强直性脊柱炎应多早在肿瘤坏死因子阻滞剂治疗？
How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
作者信息
Sieper J, Rudwaleit M
机构信息
Medical Department, Rheumatology, Campus Benjamin Franklin, Charité, Hindenburgdamm 30, 12200 Berlin, Germany.
出版信息
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv61-4. doi: 10.1136/ard.2005.042432.
Abstract
Recognition and treatment of ankylosing spondylitis (AS) in the early stages of the disease has yet to be established. This paper considers the evidence available and the questions that need to be answered regarding the benefits of early diagnosis and treatment with tumour necrosis factor (TNF) blockers in AS. The authors conclude that AS can and has to be diagnosed earlier than is being done at present, before radiological changes are evident, and the potential of TNF blockers to induce long term remission if given early enough needs to be clarified.
摘要
强直性脊柱炎（AS）疾病早期的识别与治疗方法尚未确立。本文探讨了现有证据以及关于AS早期诊断和使用肿瘤坏死因子（TNF）阻滞剂治疗的益处所需解答的问题。作者得出结论，AS能够且必须比目前更早地进行诊断，即在影像学改变明显之前，并且如果足够早期给予TNF阻滞剂诱导长期缓解的潜力需要加以阐明。
相似文献
1
How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?强直性脊柱炎应多早在肿瘤坏死因子阻滞剂治疗？
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv61-4. doi: 10.1136/ard.2005.042432.
2
Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?肿瘤坏死因子阻滞剂能否抑制强直性脊柱炎未来结构损伤的进展？
Ann Rheum Dis. 2008 Sep;67(9):1354. doi: 10.1136/ard.2007.082537.
3
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.阿达木单抗、依那西普和英夫利昔单抗治疗强直性脊柱炎：系统评价与经济学评估
Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. doi: 10.3310/hta11280.
4
Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?肿瘤坏死因子阻滞剂与强直性脊柱炎的结构重塑：何为现实，何为虚幻？
Ann Rheum Dis. 2007 Jun;66(6):709-11. doi: 10.1136/ard.2007.071159.
5
[Spondyloarthritis].[脊柱关节炎]
Z Rheumatol. 2004 Jun;63(3):185-6. doi: 10.1007/s00393-004-0627-y.
6
An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.一项关于在强直性脊柱炎中开始使用肿瘤坏死因子阻断剂的国际研究。
Ann Rheum Dis. 2006 Dec;65(12):1620-5. doi: 10.1136/ard.2005.042630. Epub 2006 Feb 7.
7
BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.英国风湿病学会关于成人强直性脊柱炎患者使用肿瘤坏死因子-α阻滞剂的处方指南。英国风湿病学会工作组报告
Rheumatology (Oxford). 2005 Jul;44(7):939-47. doi: 10.1093/rheumatology/keh669. Epub 2005 May 18.
8
TNF inhibitors for ankylosing spondylitis in the real world.
Rheumatol Int. 2007 Dec;28(2):199-200. doi: 10.1007/s00296-007-0394-6. Epub 2007 Jun 30.
9
Therapeutic controversies: tumor necrosis factor α inhibitors in ankylosing spondylitis.治疗争议：肿瘤坏死因子 α 抑制剂在强直性脊柱炎中的应用。
Rheum Dis Clin North Am. 2012 Aug;38(3):613-33. doi: 10.1016/j.rdc.2012.08.004. Epub 2012 Sep 15.
10
Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?治疗对 TNF 抑制剂应答不佳的强直性脊柱炎患者：是否有其他选择？
Curr Opin Rheumatol. 2012 May;24(3):252-60. doi: 10.1097/BOR.0b013e3283524b82.
引用本文的文献
1
Clinical Manifestations and Diagnosis of Axial Spondyloarthritis.中轴型脊柱关节炎的临床表现与诊断。
J Clin Rheumatol. 2021 Dec 1;27(8):e547-e560. doi: 10.1097/RHU.0000000000001575.
2
Diagnostic Delay in Ankylosing Spondylitis: Related Factors and Prognostic Outcomes.强直性脊柱炎的诊断延迟：相关因素及预后结果
Arch Rheumatol. 2015 Aug 16;31(1):24-30. doi: 10.5606/ArchRheumatol.2016.5562. eCollection 2016 Mar.
3
A Variant in Is Associated with the Risk of Ankylosing Spondylitis in Koreans.一个基因变异与韩国人患强直性脊柱炎的风险相关。
Genomics Inform. 2017 Jun;15(2):65-68. doi: 10.5808/GI.2017.15.2.65. Epub 2017 Jun 15.
4
The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology.非放射学中轴型脊柱关节炎、放射学中轴型脊柱关节炎和强直性脊柱炎：风湿病的纠结难题
Int J Rheumatol. 2017;2017:1824794. doi: 10.1155/2017/1824794. Epub 2017 May 7.
5
Tuberculous bursitis of the greater trochanter mimicking ankylosing spondylitis.酷似强直性脊柱炎的大转子结核性滑囊炎。
Eur J Rheumatol. 2015 Mar;2(1):31-32. doi: 10.5152/eurjrheumatol.2015.0069. Epub 2015 Mar 1.
6
Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.戈利木单抗治疗强直性脊柱炎：NICE 单技术评估
Pharmacoeconomics. 2013 May;31(5):415-25. doi: 10.1007/s40273-013-0049-2.
7
The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist.评估脊柱关节炎国际学会的概念和标准对轴性脊柱关节炎和外周脊柱关节炎的分类：儿科风湿病学家的批判性评价。
Pediatr Rheumatol Online J. 2012 May 31;10(1):14. doi: 10.1186/1546-0096-10-14.
8
Developments in therapies for spondyloarthritis.脊柱关节炎治疗方法的进展。
Nat Rev Rheumatol. 2012 Apr 10;8(5):280-7. doi: 10.1038/nrrheum.2012.40.
9
Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE).依那西普治疗晚期强直性脊柱炎的风湿学指标和肺功能试验的疗效：一项随机、双盲、安慰剂对照研究（脊柱）的结果。
Ann Rheum Dis. 2011 May;70(5):799-804. doi: 10.1136/ard.2010.139261. Epub 2011 Feb 13.
10
Human leukocyte antigen-B*2705 is the predominant subtype in the Korean population with ankylosing spondylitis, unlike in other Asians.与其他亚洲人不同，人类白细胞抗原-B*2705是韩国强直性脊柱炎患者中的主要亚型。
Rheumatol Int. 2008 Nov;29(1):43-6. doi: 10.1007/s00296-008-0602-z. Epub 2008 May 21.
本文引用的文献
1
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial.非甾体抗炎药可降低强直性脊柱炎患者的影像学进展：一项随机临床试验。
Arthritis Rheum. 2005 Jun;52(6):1756-65. doi: 10.1002/art.21054.
2
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.英夫利昔单抗持续治疗3年后强直性脊柱炎患者停用抗TNF治疗的临床反应。
Arthritis Res Ther. 2005;7(3):R439-44. doi: 10.1186/ar1693. Epub 2005 Feb 21.
3
How should we manage early rheumatoid arthritis? From imaging to intervention.我们应如何管理早期类风湿性关节炎？从影像学检查到干预措施。
Curr Opin Rheumatol. 2005 May;17(3):280-5. doi: 10.1097/01.bor.0000160779.05389.95.
4
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept.强直性脊柱炎患者在接受肿瘤坏死因子α受体融合蛋白依那西普治疗前后的脊柱磁共振成像检查。
Arthritis Rheum. 2005 Apr;52(4):1216-23. doi: 10.1002/art.20977.
5
The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?早期强直性脊柱炎的诊断与分类挑战：我们是否需要新的标准？
Arthritis Rheum. 2005 Apr;52(4):1000-8. doi: 10.1002/art.20990.
6
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).英夫利昔单抗治疗强直性脊柱炎患者的疗效与安全性：一项随机、安慰剂对照试验（ASSERT）的结果
Arthritis Rheum. 2005 Feb;52(2):582-91. doi: 10.1002/art.20852.
7
Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.在早期预后不良的类风湿性关节炎中，除甲氨蝶呤外，早期使用英夫利昔单抗治疗可减少滑膜炎和损伤的磁共振成像证据，在停用英夫利昔单抗后仍有持续益处：一项为期十二个月的随机、双盲、安慰剂对照试验的结果。
Arthritis Rheum. 2005 Jan;52(1):27-35. doi: 10.1002/art.20712.
8
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.肿瘤坏死因子拮抗剂再次给药治疗活动性强直性脊柱炎患者的长期疗效及安全性
Rheumatology (Oxford). 2005 Mar;44(3):342-8. doi: 10.1093/rheumatology/keh475. Epub 2004 Nov 23.
9
Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care.基层医疗中强直性脊柱炎（包括放射学前期和放射学表现期）的早期转诊建议
Ann Rheum Dis. 2005 May;64(5):659-63. doi: 10.1136/ard.2004.028753. Epub 2004 Nov 4.
10
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.一项评估依那西普治疗强直性脊柱炎的多中心随机临床试验结果
Ann Rheum Dis. 2004 Dec;63(12):1594-600. doi: 10.1136/ard.2004.020875. Epub 2004 Sep 2.
Zotero 插件